# Priyabrata Mukherjee

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 110 papers | 15,203 citations | 34105 52 h-index | 24982 109 g-index |
| 118 all docs | 118 docs citations | 118 times ranked | 18832 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Revealing macropinocytosis using nanoparticles. Molecular Aspects of Medicine, 2022, 83, 100993. | 6.4 | 25 |
| 2 | Synergistic interventional photothermal therapy and immunotherapy using an iron oxide nanoplatform for the treatment of pancreatic cancer. Acta Biomaterialia, 2022, 138, 453-462. | 8.3 | 44 |
| 3 | Vascular Endothelial Growth Factor as an Immediate-Early Activator of Ultraviolet-Induced Skin Injury. Mayo Clinic Proceedings, 2022, 97, 154-164. | 3.0 | 8 |
| 4 | Disabling partners in crime: Gold nanoparticles disrupt multicellular communications within the tumor microenvironment to inhibit ovarian tumor aggressiveness. Materials Today, 2022, , . | 14.2 | 5 |
| 5 | Targeting BMI1 mitigates chemoresistance in ovarian cancer. Genes and Diseases, 2022, 9, 1415-1418. | 3.4 | 0 |
| 6 | Gold nanoparticles inhibit activation of cancer-associated fibroblasts by disrupting communication from tumor and microenvironmental cells. Bioactive Materials, 2021, 6, 326-332. | 15.6 | 31 |
| 7 | Strategies for Delivering Nanoparticles across Tumor Blood Vessels. Advanced Functional Materials, 2021, 31, 2007363. | 14.9 | 46 |
| 8 | Hybrid Nanosystems for Biomedical Applications. ACS Nano, 2021, 15, 2099-2142. | 14.6 | 100 |
| 9 | Experimental conditions influence the formation and composition of the corona around gold nanoparticles. Cancer Nanotechnology, 2021, 12, 1. | 3.7 | 32 |
| 10 | Small Non-Coding-RNA in Gynecological Malignancies. Cancers, 2021, 13, 1085. | 3.7 | 20 |
| 11 | Nano-ablative immunotherapy for cancer treatment. Nanophotonics, 2021, 10, 3247-3266. | 6.0 | 4 |
| 12 | Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer. ACS Applied Materials & Interfaces, 2021, 13, 49614-49630. | 8.0 | 21 |
| 13 | Evaluation of I-TAC as a potential early plasma marker to differentiate between critical and non-critical COVID-19. Cell Stress, 2021, 6, 6-16. | 3.2 | 3 |
| 14 | Unraveling Autocrine Signaling Pathways through Metabolic Fingerprinting in Serous Ovarian Cancer Cells. Biomedicines, 2021, 9, 1927. | 3.2 | 7 |
| 15 | Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research. Cancers, 2021, 13, 6288. | 3.7 | 15 |
| 16 | KRCC1: A potential therapeutic target in ovarian cancer. FASEB Journal, 2020, 34, 2287-2300. | 0.5 | 5 |
| 17 | Sepsis in the era of data-driven medicine: personalizing risks, diagnoses, treatments and prognoses. Briefings in Bioinformatics, 2020, 21, 1182-1195. | 6.5 | 29 |
| 18 | When the chains do not break: the role of USP10 in physiology and pathology. Cell Death and Disease, 2020, 11, 1033. | 6.3 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome. Science Advances, 2020, 6, eaba5379. | 10.3 | 35 |
| 20 | Ubiquitinâ€binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer. FASEB Journal, 2020, 34, 12024-12039. | 0.5 | 10 |
| 21 | Cystathionine beta synthase regulates mitochondrial dynamics and function in endothelial cells. FASEB Journal, 2020, 34, 9372-9392. | 0.5 | 23 |
| 22 | Analysing the nanoparticle-protein corona for potential molecular target identification. Journal of Controlled Release, 2020, 322, 122-136. | 9.9 | 33 |
| 23 | Cystathione Î²-synthase regulates HIF-1Î± stability through persulfidation of PHD2. Science Advances, 2020, 6, . | 10.3 | 24 |
| 24 | <p>Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro</p>. International Journal of Nanomedicine, 2020, Volume 15, 991-1003. | 6.7 | 18 |
| 25 | Micro <scp>RNA</scp> â€195 controls <scp>MICU</scp> 1 expression and tumor growth in ovarian cancer. EMBO Reports, 2020, 21, e48483. | 4.5 | 29 |
| 26 | Targeting the TGFÎ² pathway in uterine carcinosarcoma. Cell Stress, 2020, 4, 252-260. | 3.2 | 7 |
| 27 | Nanoparticle Interactions with the Tumor Microenvironment. Bioconjugate Chemistry, 2019, 30, 2247-2263. | 3.6 | 66 |
| 28 | On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology, 2019, 14, 629-635. | 31.5 | 149 |
| 29 | Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine. Cell Stress, 2019, 3, 267-279. | 3.2 | 45 |
| 30 | Hydrogen sulfide signaling in mitochondria and disease. FASEB Journal, 2019, 33, 13098-13125. | 0.5 | 162 |
| 31 | Gold Nanoparticle Transforms Activated Cancer-Associated Fibroblasts to Quiescence. ACS Applied Materials & Interfaces, 2019, 11, 26060-26068. | 8.0 | 40 |
| 32 | Gold Nanoparticles Disrupt Tumor Microenvironment - Endothelial Cell Cross Talk To Inhibit Angiogenic Phenotypes <i>in Vitro</i>. Bioconjugate Chemistry, 2019, 30, 1724-1733. | 3.6 | 38 |
| 33 | LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Research, 2018, 78, 1923-1934. | 0.9 | 61 |
| 34 | Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Molecular Cancer Therapeutics, 2018, 17, 39-49. | 4.1 | 40 |
| 35 | Cystathionine Î²â€synthase regulates mitochondrial morphogenesis in ovarian cancer. FASEB Journal, 2018, 32, 4145-4157. | 0.5 | 33 |
| 36 | Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Molecular Cancer Therapeutics, 2018, 17, 2136-2143. | 4.1 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Cystathionine Î²-Synthase Is Necessary for Axis Development in Vivo. Frontiers in Cell and Developmental Biology, 2018, 6, 14. | 3.7 | 14 |
| 38 | Probing Cellular Processes Using Engineered Nanoparticles. Bioconjugate Chemistry, 2018, 29, 1793-1808. | 3.6 | 11 |
| 39 | MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nature Communications, 2017, 8, 14634. | 12.8 | 118 |
| 40 | BMI1, a new target of CK2Î±. Molecular Cancer, 2017, 16, 56. | 19.2 | 18 |
| 41 | Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget, 2016, 7, 72845-72859. | 1.8 | 13 |
| 42 | Hepatoma derived growth factor (HDGF) dynamics in ovarian cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 2016, 21, 329-339. | 4.9 | 22 |
| 43 | Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy, 2016, 12, 659-670. | 9.1 | 61 |
| 44 | Mitochondrial BMI1 maintains bioenergetic homeostasis in cells. FASEB Journal, 2016, 30, 4042-4055. | 0.5 | 18 |
| 45 | Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano, 2016, 10, 10636-10651. | 14.6 | 134 |
| 46 | MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 983-993. | 1.9 | 25 |
| 47 | Cystathionine Î²â€synthase regulates endothelial function via protein<i>S</i>â€sulfhydration. FASEB Journal, 2016, 30, 441-456. | 0.5 | 102 |
| 48 | Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget, 2016, 7, 15093-15104. | 1.8 | 61 |
| 49 | Role of cystathionine beta synthase in lipid metabolism in ovarian cancer. Oncotarget, 2015, 6, 37367-37384. | 1.8 | 31 |
| 50 | Hepatomaâ€Derived Growth Factor (HDGF) Acts in Ovarian Cancer via Distinct Intracellular and Extracellular Mechanisms. FASEB Journal, 2015, 29, 726.6. | 0.5 | 0 |
| 51 | Understanding Proteinâ€"Nanoparticle Interaction: A New Gateway to Disease Therapeutics. Bioconjugate Chemistry, 2014, 25, 1078-1090. | 3.6 | 76 |
| 52 | Tuning Pharmacokinetics and Biodistribution of a Targeted Drug Delivery System Through Incorporation of a Passive Targeting Component. Scientific Reports, 2014, 4, 5669. | 3.3 | 41 |
| 53 | Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget, 2014, 5, 6453-6465. | 1.8 | 62 |
| 54 | Probing Novel Roles of the Mitochondrial Uniporter in Ovarian Cancer Cells Using Nanoparticles. Journal of Biological Chemistry, 2013, 288, 17610-17618. | 3.4 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6700-6705. | 7.1 | 208 |
| 56 | Inhibiting the Growth of Pancreatic Adenocarcinoma In Vitro and In Vivo through Targeted Treatment with Designer Gold Nanotherapeutics. PLoS ONE, 2013, 8, e57522. | 2.5 | 27 |
| 57 | Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression and Drug Resistance. PLoS ONE, 2013, 8, e79167. | 2.5 | 205 |
| 58 | Identifying New Therapeutic Targets via Modulation of Protein Corona Formation by Engineered Nanoparticles. PLoS ONE, 2012, 7, e33650. | 2.5 | 85 |
| 59 | Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chemical Society Reviews, 2012, 41, 2943. | 38.1 | 725 |
| 60 | Switching the Targeting Pathways of a Therapeutic Antibody by Nanodesign. Angewandte Chemie - International Edition, 2012, 51, 1563-1567. | 13.8 | 41 |
| 61 | Back Cover: Switching the Targeting Pathways of a Therapeutic Antibody by Nanodesign (Angew. Chem.) Tj ETQq1 1 0.784314 rgBT /Ov | 13.8 | 0 |
| 62 | A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity. Chemical Communications, 2011, 47, 8530. | 4.1 | 14 |
| 63 | Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer. PLoS ONE, 2011, 6, e17918. | 2.5 | 74 |
| 64 | Designing Nanoconjugates to Effectively Target Pancreatic Cancer Cells In Vitro and In Vivo. PLoS ONE, 2011, 6, e20347. | 2.5 | 60 |
| 65 | Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 580-587. | 3.3 | 196 |
| 66 | Inorganic Nanoparticles in Cancer Therapy. Pharmaceutical Research, 2011, 28, 237-259. | 3.5 | 323 |
| 67 | Efficient Delivery of Gold Nanoparticles by Dual Receptor Targeting. Advanced Materials, 2011, 23, 5034-5038. | 21.0 | 48 |
| 68 | Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 965-973. | 1.7 | 32 |
| 69 | Synthesis of Silver Nanocubes by Photoreduction of Silver Salts in the Presence of Proteins. International Journal of Green Nanotechnology, 2011, 3, 134-139. | 0.3 | 2 |
| 70 | Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles. PLoS ONE, 2011, 6, e24374. | 2.5 | 315 |
| 71 | Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Advanced Drug Delivery Reviews, 2010, 62, 346-361. | 13.7 | 376 |
| 72 | A core-shell nanomaterial with endogenous therapeutic and diagnostic functions. Cancer Nanotechnology, 2010, 1, 13-18. | 3.7 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14541-14546. | 7.1 | 126 |
| 74 | Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide. Nanotechnology, 2010, 21, 305102. | 2.6 | 48 |
| 75 | Effect of Nanoparticle Surface Charge at the Plasma Membrane and Beyond. Nano Letters, 2010, 10, 2543-2548. | 9.1 | 537 |
| 76 | Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opinion on Drug Delivery, 2010, 7, 753-763. | 5.0 | 437 |
| 77 | Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. Journal of Materials Chemistry, 2010, 20, 547-554. | 6.7 | 85 |
| 78 | MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer. Cancer Research, 2009, 69, 9090-9095. | 0.9 | 229 |
| 79 | In vivo toxicity studies of europium hydroxide nanorods in mice. Toxicology and Applied Pharmacology, 2009, 240, 88-98. | 2.8 | 90 |
| 80 | Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. Journal of Nanobiotechnology, 2008, 6, 2. | 9.1 | 226 |
| 81 | Biological properties of â€œnakedâ€•metal nanoparticlesâ˜†. Advanced Drug Delivery Reviews, 2008, 60, 1289-1306. | 13.7 | 771 |
| 82 | Fabrication of Gold Nanoparticle for Potential Application in Multiple Myeloma. Journal of Biomedical Nanotechnology, 2008, 4, 499-507. | 1.1 | 14 |
| 83 | Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent. Cancer Research, 2008, 68, 1970-1978. | 0.9 | 332 |
| 84 | Role of Hedgehog Signaling in Ovarian Cancer. Clinical Cancer Research, 2008, 14, 7659-7666. | 7.0 | 113 |
| 85 | Application of Gold Nanoparticles for Targeted Therapy in Cancer. Journal of Biomedical Nanotechnology, 2008, 4, 99-132. | 1.1 | 68 |
| 86 | Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. Journal of Experimental Therapeutics and Oncology, 2008, 7, 313-26. | 0.5 | 69 |
| 87 | Lanthanide Phosphate Nanorods as Inorganic Fluorescent Labels in Cell Biology Research. Clinical Chemistry, 2007, 53, 2029-2031. | 3.2 | 41 |
| 88 | Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2007, 3, 224-238. | 3.3 | 166 |
| 89 | Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. Journal of Nanobiotechnology, 2007, 5, 4. | 9.1 | 175 |
| 90 | Inorganic phosphate nanorods are a novel fluorescent label in cell biology. Journal of Nanobiotechnology, 2006, 4, 11. | 9.1 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Biorelevant mesoporous silicon / polymer composites: directed assembly, disassembly, and controlled release. Biomedical Microdevices, 2006, 8, 9-15. | 2.8 | 41 |
| 92 | The use of microorganisms for the formation of metal nanoparticles and their application. Applied Microbiology and Biotechnology, 2006, 69, 485-492. | 3.6 | 887 |
| 93 | Gold Nanoparticles Bearing Functional Anti-Cancer Drug and Anti-Angiogenic Agent: A "2 in 1" System with Potential Application in Cancer Therapeutics. Journal of Biomedical Nanotechnology, 2005, 1, 224-228. | 1.1 | 39 |
| 94 | Porous silicon-based scaffolds for tissue engineering and other biomedical applications. Physica Status Solidi (A) Applications and Materials Science, 2005, 202, 1451-1455. | 1.8 | 131 |
| 95 | Antiangiogenic Properties of Gold Nanoparticles. Clinical Cancer Research, 2005, 11, 3530-3534. | 7.0 | 426 |
| 96 | Inhibition of Vascular Permeability Factor/Vascular Endothelial Growth Factor-mediated Angiogenesis by the Kruppel-like Factor KLF2*. Journal of Biological Chemistry, 2005, 280, 28848-28851. | 3.4 | 147 |
| 97 | Regulatory role of dynaminâ€2 in VEGFRâ€2/KDRâ€mediated endothelial signaling. FASEB Journal, 2005, 19, 1692-1694. | 0.5 | 75 |
| 98 | Î¼ Opioid Receptor Stimulates a Growth Promoting and Pro-Angiogenic Tumor Microenvironment by Transactivating VEGF Receptor-2/Flk-1.. Blood, 2005, 106, 3687-3687. | 1.4 | 0 |
| 99 | Preparation and stabilization of gold nanoparticles formed by in situ reduction of aqueous chloroaurate ions within surface-modified mesoporous silica. Microporous and Mesoporous Materials, 2003, 58, 201-211. | 4.4 | 96 |
| 100 | Extracellular biosynthesis of silver nanoparticles using the fungus Fusarium oxysporum. Colloids and Surfaces B: Biointerfaces, 2003, 28, 313-318. | 5.0 | 1,505 |
| 101 | Characterization and Catalytic Activity of Gold Nanoparticles Synthesized by Autoreduction of Aqueous Chloroaurate Ions with Fumed Silica. Chemistry of Materials, 2002, 14, 1678-1684. | 6.7 | 107 |
| 102 | Extracellular Synthesis of Gold Nanoparticles by the Fungus Fusarium oxysporum. ChemBioChem, 2002, 3, 461. | 2.6 | 560 |
| 103 | Enzyme Mediated Extracellular Synthesis of CdS Nanoparticles by the Fungus,Fusarium oxysporum. Journal of the American Chemical Society, 2002, 124, 12108-12109. | 13.7 | 509 |
| 104 | Phase transfer of aqueous colloidal gold particles into organic solutions containing fatty amine molecules. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2001, 181, 255-259. | 4.7 | 91 |
| 105 | Bioreduction of AuCl4â˘’ Ions by the Fungus, Verticillium sp. and Surface Trapping of the Gold Nanoparticles Formed D.M. and S.S. thank the Council of Scientific and Industrial Research (CSIR), Government of India, for financial assistance.. Angewandte Chemie - International Edition, 2001, 40, 3585. | 13.8 | 768 |
| 106 | Fungus-Mediated Synthesis of Silver Nanoparticles and Their Immobilization in the Mycelial Matrix: A Novel Biological Approach to Nanoparticle Synthesis. Nano Letters, 2001, 1, 515-519. | 9.1 | 1,181 |
| 107 | Size discrimination of colloidal nanoparticles by thiol-functionalized MCM-41 mesoporous molecular sieves. PhysChemComm, 2000, 3, 15. | 0.8 | 6 |
| 108 | Amphoterization of Colloidal Gold Particles by Capping with Valine Molecules and Their Phase Transfer from Water to Toluene by Electrostatic Coordination with Fatty Amine Molecules. Langmuir, 2000, 16, 9775-9783. | 3.5 | 64 |

| # | Article | IF | Citations |
| --- | --- | --- | --- |
| 109 | Enhancement in the reaction rates in the hydroxylation of aromatics over TS-1/H2O2 under solvent-free triphase conditions. Catalysis Today, 1999, 49, 185-191. | 4.4 | 47 |
| 110 | Triphase Catalysis over Titaniumâ€"Silicate Molecular Sieves under Solvent-free Conditions. Journal of Catalysis, 1998, 178, 101-107. | 6.2 | 93 |